Navigation Links
Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
Date:1/12/2009

PALO ALTO, Calif., Jan. 12 /PRNewswire/ -- Anacor Pharmaceuticals today announced that it has achieved its first candidate selection milestone payment of $3 million from its collaboration partner, GlaxoSmithKline. Anacor may receive future milestone payments and royalties should this product candidate progress to clinical development and commercial sales.

"We are pleased with the scientific progress we have made as a result of the alliance we have built between our team and GSK. The strength of this collaboration is reflected in our ability to move our first compound into preclinical development only 15 months since starting our work together," said Jacob J. Plattner, Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. "We believe that our boron-based platform will continue to allow the collaboration team to successfully identify additional novel product candidates."

In October 2007, Anacor and GlaxoSmithKline announced a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor's proprietary boron-based chemistry for use against selected antiviral and antibacterial targets.

In December 2008, Anacor closed a $50 million preferred stock financing with participation from GlaxoSmithKline, Schering Corporation and existing investors, including Rho Capital Partners, Venrock Associates, Care Capital and Aberdare Ventures. Proceeds from the financing will be used to further develop Anacor's product pipeline based on its boron chemistry platform. The combined ownership of GlaxoSmithKline and Schering Corporation is less than 20 percent of Anacor's outstanding shares.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit http://www.anacor.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding our ability to identify and efficiently develop product candidates using boron chemistry and our ability to secure milestone or royalty payments from GlaxoSmithKline for these compounds. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward- looking statements include, but are not limited to, undesirable effects from our product candidates, clinical failure at later stages of development and unexpected termination of existing partnerships. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anacor Files Registration Statement for Initial Public Offering
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
4. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
5. Anacor Raises $50 Million in Equity Financing
6. Pharsight Achieves First License Sale for Public-Source Database
7. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Signalife Achieves $1.98 Million Sales Orders Thus Far
10. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
11. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... annual meeting and educational conference of the American Association of Bioanalysts (AAB) and ... Galleria Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... ... QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and who ... Jersey and Delaware, are encouraged to submit proposals. QED, now in its tenth ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, ... has doubled in size over the past six months with the acquisition of businesses ... joins CSM as Chief Financial Officer. Roger has over 25 years of experience ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... ... specializing in medical device compliance and commercialization, has just released version 9.0 of ... work into this latest version of Cockpit,” says David Cronin, CEO of Cognition. ...
Breaking Biology Technology:
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):